All In Biotech

Drug Trial Radar · NCT00044824

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Aug 21, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Planned (sponsor's estimate)

Start

Feb 2002

Primary completion

Oct 2003

Study completion Oct 2003

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 17, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma

Conditions

  • Asthma

Interventions

  • FexofenadineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Forced Expiratory Volume FEV1

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • Aventis Pharmaceuticals Inc.

    Bridgewater, New Jersey

  • Sanofi-Aventis Admnistrative Office

    Costa Rica, Costa Rica

  • Sanofi-Aventis Administrative Office

    Guatemala City, Guatemala

  • sanofi-aventis Hungaria

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    México, Mexico

  • sanofi-aventis Poland

    Warsaw, Poland

  • Sanofi-Aventis Aministrative Office

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.